GBT to Announce Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021

Rhea-AI Summary

Global Blood Therapeutics (GBT) will release its fourth quarter and full year 2020 financial results on February 24, 2021, after the market closes. A conference call is scheduled for the same day at 4:30 p.m. ET to discuss these results along with a general business update. Interested parties can listen in through a live audio webcast via GBT’s website. GBT focuses on treatments for sickle cell disease, including its FDA-approved drug Oxbryta and ongoing pipeline efforts with inclacumab and GBT021601.

Positive

• Scheduled release of fourth quarter and full year 2020 financial results could indicate progress in financial performance.
• Conducting a conference call to provide business updates suggests transparency and engagement with investors.

Negative

• None.

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report fourth quarter and full year 2020 financial results on Wednesday, February 24, 2021, after U.S. financial markets close.

Management will host a conference call on Wednesday, February 24, 2021, at 4:30 p.m. ET to provide a general business update and to discuss fourth quarter and full year 2020 financial results. To participate in the conference call, please dial 877-407-3982 (domestic) or 201-493-6780 (international). A live audio webcast of the conference call can be accessed on GBT’s website at www.gbt.com under the Investors section. An archived audio webcast will be available for one month following the event.

About Global Blood Therapeutics
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta^® (voxelotor), the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company’s next generation hemoglobin S polymerization inhibitor. In addition, GBT’s drug discovery teams are working on new targets to develop the next generation of treatments for SCD. To learn more, please visit www.gbt.com and follow the company on Twitter @GBT_news.

Contact:
Steven Immergut (media)
650.410.3258
simmergut@gbt.com

Courtney Roberts (investors)
650.351.7881
croberts@gbt.com

FAQ

When will GBT report its fourth quarter 2020 financial results?

GBT will report its fourth quarter and full year 2020 financial results on February 24, 2021.

What time is the conference call for GBT's financial results?

The conference call to discuss GBT's financial results will be held at 4:30 p.m. ET on February 24, 2021.

How can I listen to GBT's conference call?

You can listen to GBT's conference call via a live audio webcast on their website.

What is GBT's focus in drug development?

GBT is focused on developing treatments for sickle cell disease, including the FDA-approved Oxbryta.